Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGeisinger Health PlanGeisinger Health Plan Lyfgenia Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentGeisinger Health PlanPolicy N/A

    Lyfgenia (lovotibeglogene autotemcel) prior authorization form and requirements

    Customize your policy alerts

    Sign up for all Geisinger Health Plan policy alerts

    Know when Geisinger Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization form and requirements for Lyfgenia (lovotibeglogene autotemcel) for Geisinger Health Plan members; directed to prescribers and service providers submitting requests for this gene therapy.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyLyfgenia (lovotibeglogene autotemcel) prior authorization form and requirements
    Policy CodePolicy N/A
    Change TypeAdministrative — form guidance (no material coverage changes)
    Effective DateJan 5, 2026
    Next Review DateN/A
    Key ActionSubmit the completed prior authorization form with required clinical documentation via PromptPA or fax to 570-271-5610.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1/5/2026form effective date
    1 HCPCS fieldbilling codes
    3 requiredeligibility checkpoints

    Coverage Criteria — Eligibility and Exclusions

    Initial therapy / eligibility

    Covered when ALL of the following are met (checkboxes on the form must be selected and documentation submitted):

    Primary eligibility checklist: Patient is clinically stable for transplantation based on the prescriber's assessment; patient has NOT received a prior allogeneic hematopoietic stem cell transplant; patient has sickle cell disease with confirmatory genetic testing.

    Each item corresponds to a required checkbox on the form.

    Clinical complication evidence: At least one of: history of vaso-occlusive episodes requiring a medical facility visit (e.g., pain crises, acute chest syndrome, splenic sequestration, priapism), OR currently receiving chronic transfusion therapy for recurrent vaso-occlusive episodes.

    Form requires documentation of the event(s) and associated clinical records (e.g., ED or hospital visits) as applicable.

    The checklist on the prior authorization form includes an explicit exclusion: the patient must not have received a prior allogeneic hematopoietic stem cell transplant. The form provides a checkbox for the prescriber to confirm this; if that box is not checked (indicating a prior allogeneic transplant), the request does not meet this coverage criterion and should be handled as excluded per the form.

    Policy Summary
    PayerGeisinger Health Plan
    PolicyLyfgenia (lovotibeglogene autotemcel) prior authorization form and requirements
    Policy CodePolicy N/A
    Change TypeAdministrative — form guidance (no material coverage changes)
    Effective DateJan 5, 2026
    Next Review DateN/A
    Key ActionSubmit the completed prior authorization form with required clinical documentation via PromptPA or fax to 570-271-5610.
    SourceLink
    On This Page
    Coverage Criteria — Eligibility and ExclusionsRequested Billing CodesPrior Authorization, Documentation, and Submission InstructionsTherapy BackgroundKey Definitions and Clinical Terms

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Requested Billing Codes

    Requested billing codesHCPCS
    HCPCS code (required)Form requests HCPCS code for the drug/infusion (exact code to be provided by requester)
    Requested billing codes - form fieldsmixed
    DX code (required)Diagnosis code field required on the form
    HCPCS code (required)HCPCS code field required on the form

    Prior Authorization, Documentation, and Submission Instructions

    Prior Authorization

    Prior authorization submission required

    Prior authorization must be submitted either online through PromptPA or by faxing the completed prior authorization form and required clinical documentation to Geisinger Health Plan.

    • Online submission: https://ghp.promptpa.com (PromptPA)
    • Fax submission: 570-271-5610 — include the completed Lyfgenia prior authorization form and all supporting documentation
    Step Therapy

    No step therapy listed

    No step therapy or sequencing requirements are specified on the Lyfgenia prior authorization form.

    Documentation Required

    Documentation required with PA form

    Include the completed Lyfgenia prior authorization form plus relevant clinical documentation demonstrating eligibility.

    • Recent chart/clinic notes
    • Diagnostic evaluations and test results (including confirmatory genetic testing for sickle cell disease)
    • Documentation of vaso-occlusive episode history (e.g., ED or hospital visits) or records showing current chronic transfusion therapy, as applicable
    • Completed form fields: diagnosis, DX code, and HCPCS code (HCPCS code entry is required on the form)
    Denial Risk

    Incomplete or missing documentation may cause denial

    Failure to submit the completed form or the required supporting documentation may result in denial or delay of the prior authorization request.

    • Missing required items on the form (e.g., diagnosis, DX code, HCPCS code) can trigger denial
    • Incomplete clinical documentation (chart notes, diagnostic tests, genetic confirmation, or transfusion history) may cause processing delays or denial

    Therapy Background

    Lyfgenia (lovotibeglogene autotemcel) is a gene therapy for sickle cell disease. The prior authorization form is intended to document patient eligibility for treatment and to collect required clinical support. Key items requested on the form include confirmation that the patient is clinically stable for transplantation per the prescriber, confirmation that the patient has not had a prior allogeneic hematopoietic stem cell transplant, and documentation of confirmatory genetic testing for sickle cell disease. The form also requires evidence of disease complications, defined as at least one of: a history of vaso‑occlusive episodes requiring a medical facility visit (for example pain crises, acute chest syndrome, splenic sequestration, or priapism) or current receipt of chronic transfusion therapy for recurrent vaso‑occlusive episodes. Submit the completed form and supporting documentation via PromptPA (https://ghp.promptpa.com) or fax to 570-271-5610.

    Key Definitions and Clinical Terms

    clinically stable for transplantation — prescriber assessment
    DefinitionClinically stable for transplantation — assessment made by the prescriber (checkbox on the prior authorization form).
    Form fieldListed as a required checkbox: 'Is clinically stable for transplantation based on the prescriber's assessment.'
    DocumentationMust submit supporting clinical documentation (e.g., recent chart/clinic notes, diagnostic evaluations, test results) with the completed form to PromptPA or fax.
    vaso-occlusive episodes — definition and examples
    DefinitionVaso-occlusive episodes — history of events requiring a medical facility visit (e.g., emergency department or hospital).
    ExamplesPain crises; acute chest syndrome; splenic sequestration; priapism (all listed as examples on the form).
    Alternate evidenceOr current receipt of chronic transfusion therapy for recurrent vaso-occlusive episodes (checkbox on the form).